- Oligomer-nucleoside phosphate conjugates
-
The invention provides small molecule drugs that are chemically modified by covalent attachment of a water soluble, non-peptidic oligomer. The conjugates of the invention, when administered by any of a number administration routes, exhibits advantages ove
- -
-
Page/Page column 40; 41
(2016/09/26)
-
- Azido nucleosides and nucleotide analogs
-
Disclosed herein are 4′-azido-substituted nucleosides, nucleotides and analogs thereof, pharmaceutical compositions that include one or more of 4′-azido-substituted nucleosides, nucleotides and analogs thereof, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating a disease and/or a condition, including an infection from a paramyxovirus and/or an orthomyxovirus, with a 4′-azido-substituted nucleoside, a nucleotide and/or an analog thereof. Examples of viral infections include a respiratory syncytial viral (RSV) and influenza infection.
- -
-
Page/Page column 76-78
(2016/06/13)
-
- COMPOSITION CONTAINING MODIFIED DERIVATIVES OF A CYTIDINE ANTIMETABOLITE FOR THE TREATMENT OF SUSCEPTIBLE DISEASE
-
The present invention relates to homo-oligomeric derivatives of a cytidine antimetabolite and its use for the treatment of susceptible diseases. The cytidine antimetabolite is preferably a compound made of 2-20 units of dFdC linked with 5' - 3' phosphate
- -
-
-
- Biological and physicochemical characterization of siRNAs modified with 2',2'-difluoro-2'-deoxycytidine (gemcitabine)
-
The use of synthetic short interfering RNAs (siRNAs) is currently a method of choice to manipulate gene expression in mammalian cells. Efforts aimed at improving siRNA biological activity, including increased silencing properties, higher substrate specifi
- Sierant, Malgorzata,Sobczak, Milena,Janicka, Magdalena,Paduszynska, Alina,Piotrzkowska, Danuta
-
scheme or table
p. 918 - 924
(2010/08/05)
-
- Novel oligonucleotides and related compounds
-
The present invention relates generally to oligonucleotides and more specifically to oligonucleotides which have a sequence including at least two CDG dinucleotides and a prodrug of an antimetabolite. The prodrug can be part of a CpG dinucleotide or may be attached elsewhere on the oligonucleotide.
- -
-
Page/Page column 15-16
(2008/06/13)
-